Christine Gaydos

PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors

P. Frost, J. Skotnicki, P. Cai, 2005, Cancer biology & therapy.

Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy.

L. Toral-Barza, J. Lucas, M. Young, 2008, Journal of medicinal chemistry.

Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.

J. Gibbons, J. Lucas, Jianxin Gu, 2010, Journal of medicinal chemistry.

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

R. Abraham, J. Gibbons, L. Toral-Barza, 2010, Cancer research.

Updates on canine hypoadrenocorticism

A. DeClue, Christine Gaydos, 2008 .